Yielding to industry objections, FDA has abandoned its proposed definition for a suspected adverse drug reaction (SADR) in its just-finalized rule on clinical trial safety reporting. The agency said ...
The choice of the dose of an anticancer drug is established in first-in-human, dose-escalation, phase 1 clinical trials involving patients with cancer for whom standard-of-care treatments are often no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback